XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jul. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Compensation Costs
The stock-based compensation costs that have been charged against income were as follows (in thousands):

13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Stock-based compensation expense by type:
Stock options
$— $— $220 $155 
Restricted stock units1,268 1,488 2,921 3,613 
Employee stock purchases
83 77 189 235 
Director deferred compensation26 24 52 41 
  Total stock-based compensation expense1,377 1,589 3,382 4,044 
Income tax benefit recognized263 369 649 926 
  Stock-based compensation expense, net of income tax$1,114 $1,220 $2,733 $3,118 
Schedule of Equity Awards Granted
We granted the following equity awards:
13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Stock options
— — 8,188 7,212 
Restricted stock unit awards
— 1,673 78,515 109,521 
Performance-based restricted stock unit awards
— — 39,567 49,978 
Deferred stock units
705 532 1,155 937 
Schedule of Stock Options Granted, Exercise Price Per Share and Weighted-average Grant Date Fair Value
Details of stock options granted, exercise price per share and the weighted-average grant date fair value were as follows:

13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Total stock options granted— — 8,188 7,212 
Exercise price$— $— $58.38 $46.22 
Fair value of stock options$— $— $26.87 $21.46 
Schedule of Shares Purchased
The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:
13-Weeks Ended26-Weeks Ended
July 29,
2023		July 30,
2022		July 29,
2023		July 30,
2022
Shares purchased9,705 7,352 16,731 21,625 
Average price per share$30.85 $36.07 $38.95 $52.62 
Weighted-average fair value at grant date$15.18 $10.65 $16.19 $15.52